NEW YORK, NY / ACCESSWIRE / September 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
MacroGenics, Inc. (NASDAQGS:MGNX)
Lawsuit on behalf of: investors who purchased February 6, 2019 - June 3, 2019
Lead Plaintiff Deadline : November 12, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/macrogenics-inc-loss-form?prid=3577&wire=1
According to the filed complaint, during the class period, MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.
Cadence Bancorporation (NYSE:CADE)
Lawsuit on behalf of: investors who purchased July 23, 2018 - July 22, 2019
Lead Plaintiff Deadline : November 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cadence-bankcorporation-loss-form?prid=3577&wire=1
According to the filed complaint, during the class period, Cadence Bancorporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate internal controls to assess credit risk; (2) as a result, certain of the Company's loans posed an increased risk of loss; (3) as a result, the Company was reasonably likely to incur significant losses for certain loans; (4) the Company's financial results would suffer a material adverse impact; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DXC Technology Company (NYSE:DXC)
Lawsuit on behalf of: investors who purchased persons and entities that purchased or otherwise acquired DXC Technology Company ("DXC") common stock pursuant and/or traceable to the registration statement and prospectus or other documents issued in connection with the April 2017 transaction by which Hewlett Packard Enterprise Company's Enterprise Services segment was spun off and merged with Computer Sciences Corporation, Inc. to form DXC.
Lead Plaintiff Deadline : November 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/dxc-technology-company-loss-form-2?prid=3577&wire=1
According to the filed complaint, (1) the planned "workforce optimization" plan involved implementing arbitrary quotas; (2) the plan would cut thousands of jobs at the Company; (3) jobs that were particularly at risk of being cut were held by longer-tenured, knowledgeable, and highly compensated senior personnel; (4) these job terminations were selectively timed to artificially inflate reported earnings and other financial metrics; (5) at the time of the formation of DXC Technology Company, J. Michael Lawrie (the incoming President, Chief Executive Officer, and Chairman of the Board at DXC) had forecasted plans for a $2.7 billion workforce reduction in the first year; (6) as a result of these workforce terminations, the Company was unlikely to deliver on client contracts; (7) that, as a result of the foregoing, the Company's clients would be dissatisfied and the relationships would be impaired; and (8) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/560175/CLASS-ACTION-UPDATE-for-MGNX-CADE-and-DXC-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
